Amarin Co. plc (AMRN) to Post Q1 2018 Earnings of ($0.05) Per Share, Jefferies Group Forecasts
Amarin Co. plc (NASDAQ:AMRN) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings estimates for Amarin in a report issued on Wednesday. Jefferies Group analyst M. Andrews expects that the biopharmaceutical company will post earnings per share of ($0.05) for the quarter. Jefferies Group also issued estimates for Amarin’s Q2 2018 earnings at ($0.06) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at ($0.15) EPS, FY2018 earnings at ($0.32) EPS and FY2019 earnings at ($0.05) EPS.
Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The firm had revenue of $53.87 million during the quarter, compared to analyst estimates of $52.73 million. The company’s revenue for the quarter was up 39.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.10) EPS.
Amarin (NASDAQ:AMRN) opened at $3.36 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.32 and a debt-to-equity ratio of -1.12. The stock has a market capitalization of $971.69, a P/E ratio of -13.44 and a beta of 0.57. Amarin has a 52-week low of $2.85 and a 52-week high of $4.60.
Several hedge funds and other institutional investors have recently bought and sold shares of AMRN. Paloma Partners Management Co bought a new position in shares of Amarin in the fourth quarter valued at $141,000. Hoylecohen LLC bought a new position in shares of Amarin in the fourth quarter valued at $142,000. Wells Fargo & Company MN increased its holdings in shares of Amarin by 15.2% in the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 5,000 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Amarin in the third quarter valued at $226,000. Finally, Stevens Capital Management LP bought a new position in shares of Amarin in the third quarter valued at $229,000. 37.28% of the stock is currently owned by institutional investors.
In other Amarin news, insider Steven B. Ketchum sold 64,683 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.40, for a total value of $284,605.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Joseph T. Kennedy sold 44,857 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $3.73, for a total value of $167,316.61. The disclosure for this sale can be found here. Insiders sold 426,720 shares of company stock valued at $1,814,296 over the last 90 days. 3.72% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/amarin-co-plc-amrn-to-post-q1-2018-earnings-of-0-05-per-share-jefferies-group-forecasts/1905966.html.
Amarin Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.